1-[(6-氟-2,9-二氢-9-甲基-1-氧代-2-苯基-1H-吡啶并[3,4-b]吲哚-4-基)羰基]-吡咯烷 | 205881-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-[(6-氟-2,9-二氢-9-甲基-1-氧代-2-苯基-1H-吡啶并[3,4-b]吲哚-4-基)羰基]-吡咯烷
• 英文名称: SL651498
• 英文别名: Pyrrolidine, 1-((6-fluoro-2,9-dihydro-9-methyl-1-oxo-2-phenyl-1H-pyrido(3,4-b)indol-4-yl)carbonyl)-；6-fluoro-9-methyl-2-phenyl-4-(pyrrolidine-1-carbonyl)pyrido[3,4-b]indol-1-one
• CAS: 205881-86-3
• 化学式: C₂₃H₂₀FN₃O₂
• 分子量: 389.429
• InChiKey: QQWHWWDIFGNCLV-UHFFFAOYSA-N

物化性质

• 沸点：
  649.7±55.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：>100mM

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-fluoro-9-methyl-1-oxo-2-phenyl-2,9-dihydro-1H-pyrido[3,4-b]indole-4-carboxylic acid 生成 1-[(6-氟-2,9-二氢-9-甲基-1-氧代-2-苯基-1H-吡啶并[3,4-b]吲哚-4-基)羰基]-吡咯烷
  参考文献：
  名称：

  1H-pyrido[3,4-b]indole-4-carboxamide derivatives, preparation and

  摘要：

  通式（I）的化合物 ##STR1## 其中变量如规范中所定义，它们的制备以及它们在治疗中的应用。

  公开号：

  US06075021A1

文献信息

• DERIVES DE 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：SANOFI-SYNTHELABO

  公开号：EP0934319B1

  公开（公告）日：2002-06-05
• STABLE NANOPARTICLE FORMULATIONS
  申请人：Sanofi-Aventis U.S. LLC

  公开号：EP1895982A2

  公开（公告）日：2008-03-12
• Stable Nanoparticle Formulations
  申请人：ABU-IZZA Abdullah Khawla

  公开号：US20080038359A1

  公开（公告）日：2008-02-14

  The invention relates to pharmaceutically stable nanoparticle formulations of poorly soluble drug substances, to the processes for the preparation of such formulations, and to methods of use thereof.
• POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM
  申请人：UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

  公开号：US20150313913A1

  公开（公告）日：2015-11-05

  Provided herein are methods and formulations for treating an Autism Spectrum Disorder using low doses of an agent that enhances signaling through the GABA receptor.
• METHODS FOR TREATING PSYCHIATRIC DISORDERS
  申请人：HUH Jun R.

  公开号：US20170326356A1

  公开（公告）日：2017-11-16

  Methods for treating subjects afflicted with a psychiatric disorders [e.g., autism spectrum disorder (ASD), schizophrenia, and/or depression] are described herein. More particularly, the present invention relates to a method for treating a subject afflicted with or at risk for developing a psychiatric disorder (e.g., ASD, of which autism is a particular example) that calls for selecting a subject afflicted with or at risk for developing the psychiatric disorder based in part on previous in utero exposure to maternal immune activation (MIA) and treating the subject by administering pharmacological agents or implementing optogenetic tools or chemogenetic tools that correct dysregulated neuronal excitation/inhibition (E/I) ratios in cortical patches of the subject wherein the E/I ratio is dysregulated. A subject may also be selected for treatment using methods described herein based on the presence or detection of cortical patches having dysregulated neuronal E/I ratios.